News
Roche's Susvimo FDA Approval Marks New Era in Diabetic Macular Edema Treatment Market | DelveInsight
Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...
Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...
Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...
2d
The Manila Times on MSNKiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio ExecutionLONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...
The results of the STELLAR trial showed that the activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein achieved a significant ... Acceleron's long-term partner for FDA-approved anaemia drug ...
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...
Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK fusion-positive solid tumors. “This first full approval of an NTRK inhibitor ...
Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat neurotrophic ... Tumours with NTRK gene fusion produce an altered TRK ...
COLUMBUS, Ohio — Several synthetic dyes and food coloring will soon be taken out of food. The Food and Drug Administration is banning two synthetic food colorings, including Citrus Red 2 and ...
CGBIO, a South Korea-based company, earned the FDA’s investigational device exemption approval for its Novosis putty for spinal fusions. The bone graft incorporates rhBMP-2 and is designed to enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results